Total 2017 US revenue for ovarian cancer: $305.5M
Estimated 2026 US revenue for ovarian, breast, prostate and pancreatic cancer: $2.2 billion
"With three PARPs already approved for ovarian cancer and more set to enter the market, the key issue for developers will be finding ways to ensure that their PARP inhibitor stands out from the crowd.
In the absence of meaningful differences in efficacy and toxicity, non-clinical factors such as time-to-market, price and managed entry agreements will play a key role in securing market share.”
- Carolina do Pazo, Business Insights Analyst, DRG Oncology
Single-arm studies and surrogate endpoints do not fully provide the clinicians with the information necessary to make treatment decisions.
More follow-up studies for PARP inhibitors are needed as evidence of overall survival benefit ultimately has the greatest influence on physician prescribing decisions.
Indirect comparison of the PARP inhibitors based on the current evidence is difficult, so head-to-head assessments are needed.
Developers must find ways to differentiate their agent from the competition. In the absence of clinical differentiators, pricing, managed entry agreements and marketing will be crucial to optimize market uptake.